Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03054428 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis
A Phase 3 study of Dermatitis, Atopic and Moderate-to-Severe Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 251
- Enrollment target
- 20
- Study locations
NCT03054428 is a Phase 3 study of Dermatitis, Atopic and Moderate-to-Severe Atopic Dermatitis that has completed, run by Regeneron Pharmaceuticals. The registered enrollment target is 251 participants, below the 388-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT03054428, a Phase 3 study of Dermatitis, Atopic and Moderate-to-Severe Atopic Dermatitis, has completed, sponsored by Regeneron Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 251 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of the study was to demonstrate the efficacy of dupilumab as a monotherapy in participants ≥12 years to \<18 years of age with moderate-to-severe atopic dermatitis (AD). The secondary objective of the study was to assess the safety of dupilumab as a monotherapy in participants ≥12 years to \<18 years of age with moderate-to-severe AD.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dupilumab
Study Locations (20)
California
- Regeneron Investigational Site - Bakersfield
- Regeneron Investigational Site - Long Beach
- Regeneron Investigational Site - Rolling Hills Estates
- Regeneron Investigational Site - San Diego
- Regeneron Investigational Site - Santa Rosa
Indiana
- Regeneron Investigational Site - Evansville
- Regeneron Investigational Site - Indianapolis
- Regeneron Investigational Site - Plainfield
Colorado
- Regeneron Investigational Site - Centennial
- Regeneron Investigational Site - Denver
Georgia
- Regeneron Investigational Site - Macon
- Regeneron Investigational Site - Sandy Springs
Massachusetts
- Regeneron Investigational Site - Boston
- Regeneron Investigational Site - Boston
Alabama
- Regeneron Investigational Site - Birmingham
Arizona
- Regeneron Investigational Site - Gilbert
District of Columbia
- Regeneron Investigational Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2017-03-21 |
| Est. Completion | 2018-06-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03054428
The ClinicalTrials.gov registry entry for NCT03054428 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 388-participant average among 29 other Dermatitis, Atopic trials with a reported enrollment target (35% lower). The listed sponsor is Regeneron Pharmaceuticals, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Dermatitis, Atopic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03054428 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Indiana, Colorado.
Frequently Asked Questions
What is clinical trial NCT03054428 about?
NCT03054428 is a clinical study titled "Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis". The primary objective of the study was to demonstrate the efficacy of dupilumab as a monotherapy in participants ≥12 years to \<18 years of age with moderate-to-severe atopic dermatitis (AD). The secondary objective of the study was to assess the safety of dupilumab as a monotherapy in participants ...
What is the current status of trial NCT03054428?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 251 participants. The study started on 2017-03-21. Estimated completion is 2018-06-05.
What conditions does trial NCT03054428 study?
This clinical trial studies the following conditions: Dermatitis, Atopic, Moderate-to-Severe Atopic Dermatitis, Hypersensitivity, Immediate, Dermatitis, Dermatitis Atopic, Eczema, Skin Diseases, Skin.
What interventions are being tested in trial NCT03054428?
The interventions under investigation include: Placebo (DRUG), Dupilumab (DRUG).
Who is sponsoring clinical trial NCT03054428?
This trial is sponsored by Regeneron Pharmaceuticals, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03054428 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dermatitis, Atopic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor
RECRUITING · Phase 3
-
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
ACTIVE NOT RECRUITING · Phase 3
-
Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
COMPLETED · Phase 3
-
Study of Dupilumab Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
COMPLETED · Phase 3
-
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.